Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Grows By 36.8%

Posted by Stacy Sanders on Dec 15th, 2024

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 549,400 shares, a growth of 36.8% from the November 15th total of 401,700 shares. Based on an average daily trading volume, of 72,700 shares, the short-interest ratio is presently 7.6 days. Currently, 2.5% of the company’s stock are sold short.

Institutional Trading of Gyre Therapeutics

Several large investors have recently bought and sold shares of GYRE. Barclays PLC lifted its stake in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares during the period. Geode Capital Management LLC lifted its position in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after acquiring an additional 43,840 shares during the period. State Street Corp grew its stake in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares during the last quarter. FMR LLC acquired a new position in shares of Gyre Therapeutics in the third quarter valued at about $47,000. Finally, Advantage Alpha Capital Partners LP purchased a new position in shares of Gyre Therapeutics in the third quarter worth about $334,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Price Performance

NASDAQ GYRE traded down $0.14 during trading on Friday, hitting $9.64. The company’s stock had a trading volume of 139,162 shares, compared to its average volume of 121,390. Gyre Therapeutics has a fifty-two week low of $8.26 and a fifty-two week high of $30.40. The business’s 50 day simple moving average is $13.07 and its 200-day simple moving average is $12.59.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.